🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 16 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
03/04/2018 26,16 26,82 25,50 26,12 +0,58% 5,05% 877.600
02/04/2018 26,93 27,31 24,78 25,97 -4,03% 9,41% 1.663.400
29/03/2018 29,26 29,32 26,72 27,06 +0,07% 8,88% 3.543.800
28/03/2018 29,54 29,74 26,58 27,04 -15,29% 10,70% 2.150.700
27/03/2018 32,83 32,87 31,68 31,92 -2,06% 3,62% 438.100
26/03/2018 32,63 32,75 31,63 32,59 +1,88% 3,43% 738.000
23/03/2018 31,85 32,85 31,85 31,99 -0,03% 3,14% 571.200
22/03/2018 31,60 32,93 30,98 32,00 -0,90% 6,17% 885.300
21/03/2018 32,28 33,22 31,85 32,29 +0,03% 4,24% 940.200
20/03/2018 30,25 32,71 30,25 32,28 +7,17% 8,13% 876.100
19/03/2018 30,14 31,03 29,53 30,12 -0,26% 4,98% 1.242.000
16/03/2018 30,03 30,75 29,81 30,20 +0,37% 3,13% 2.578.000
15/03/2018 30,39 31,18 29,94 30,09 -0,99% 4,08% 1.245.900
14/03/2018 30,00 30,88 29,10 30,39 +1,67% 5,93% 1.069.400
13/03/2018 29,05 29,94 28,87 29,89 +3,53% 3,68% 942.800
12/03/2018 29,12 29,20 27,95 28,87 +0,28% 4,29% 755.900
09/03/2018 27,73 29,28 27,26 28,79 +2,89% 7,28% 892.500
08/03/2018 28,77 29,60 27,50 27,98 -4,60% 7,30% 1.010.900
07/03/2018 27,90 31,25 27,00 29,33 +9,28% 15,23% 2.090.600
06/03/2018 26,68 26,96 26,09 26,84 +0,68% 3,26% 584.400
05/03/2018 25,63 26,83 25,24 26,66 +3,61% 6,20% 477.500
02/03/2018 24,40 25,92 24,10 25,73 +3,83% 7,46% 579.100
01/03/2018 26,00 26,00 24,33 24,78 -3,77% 6,42% 502.900
28/02/2018 25,47 26,20 25,21 25,75 +1,10% 3,89% 862.100
27/02/2018 25,69 26,26 25,20 25,47 -3,12% 4,13% 884.800
26/02/2018 25,53 26,47 24,32 26,29 +3,02% 8,42% 543.100
23/02/2018 25,74 26,34 24,35 25,52 -0,55% 7,73% 573.200
22/02/2018 25,36 26,65 25,36 25,66 +2,60% 5,09% 1.095.100
21/02/2018 24,48 26,23 24,45 25,01 +3,60% 7,26% 1.147.500
20/02/2018 23,00 24,59 22,80 24,14 +0,88% 7,79% 768.900